ARWRArrowhead Pharmaceuticals, Inc.

HealthcareUSD
$89.07

Price

$89.07+455%1Y
1M+2.7%1Y+455%

Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.

Smart Score

Above average
7/10
Value71
Quality47
Momentum83
Growth9
Strongest Momentum, weakest Growth · ranked vs Healthcare peers. The five questions below judge the company on its own terms.
What they do

RNA interference (“RNAi”) is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. RNAi-based therapeutics may leverage this natural pathway of gene silencing to target and shut down specific disease-causing genes. Small molecule and antibody drugs have proven effective at inhibiting certain cell surface, intracellular, and extracellular targets.

In the company’s own words · 10-K filed Nov 25, 2025 · SEC EDGAR

P/E (TTM)-
Market Cap$11.52B
1Y Return+455%
5Y Return+31%

Arrowhead Pharmaceuticals, Inc. (ARWR) reported revenue of $75M in Q3 2026 (quarter ended June 30, 2026), up 171% from the same quarter a year earlier. That came with net loss of $194M. For the full year FY2025, revenue was $829M (+23258% year on year) and net income −$1.6M.

Raw charts

10 series · TTM

As reported to the SEC, without any scoring.

Biotechnology

Ranks #78 of 145 by Smart Score

Compare peers
BMRN+0.03%
BioMarin Pharmaceutical Inc.
SMMT-0.49%
Summit Therapeutics Inc.
CYTK-0.49%
Cytokinetics, Incorporated
KRYS+3.5%
Krystal Biotech, Inc.
MDGL+0.79%
Madrigal Pharmaceuticals, Inc.
AXSM-0.25%
Axsome Therapeutics, Inc.